Literature DB >> 15273139

High prevalence of extended-spectrum beta-lactamase-producing strains among blood isolates of Enterobacter spp. collected in a tertiary hospital during an 8-year period and their antimicrobial susceptibility patterns.

Hyunjoo Pai1, Jung Yun Hong, Jeong-Hum Byeon, Yun-Kyung Kim, Hoan-Jong Lee.   

Abstract

Of 72 blood isolates of Enterobacter spp. collected over an 8-year period, 50% (36 of 72) were derepressed or partially derepressed AmpC mutants. The extended-spectrum beta-lactamase (ESBL) production rate was 43% (31 of 72 isolates), and 67.3% (31 of 46) of extended-spectrum cephalosporin-resistant strains produced ESBLs. Thus, a confirmatory test for ESBL production is necessary for extended-spectrum cephalosporin-resistant Enterobacter spp.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15273139      PMCID： PMC478521          DOI： 10.1128/AAC.48.8.3159-3161.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  18 in total

1.  Detection of extended-spectrum beta-lactamases in clinical isolates of Enterobacter cloacae and Enterobacter aerogenes.

Authors:  E Tzelepi; P Giakkoupi; D Sofianou; V Loukova; A Kemeroglou; A Tsakris
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

2.  Detection of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae: comparison of the double-disk and three-dimensional tests.

Authors:  K S Thomson; C C Sanders
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

3.  The use of analytical isoelectric focusing for detection and identification of beta-lactamases.

Authors:  A Mathew; A M Harris; M J Marshall; G W Ross
Journal:  J Gen Microbiol       Date:  1975-05

4.  Plasmid-mediated resistance to expanded-spectrum cephalosporins among Enterobacter aerogenes strains.

Authors:  J D Pitout; K S Thomson; N D Hanson; A F Ehrhardt; P Coudron; C C Sanders
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

5.  Survey of extended-spectrum beta-lactamases in clinical isolates of Escherichia coli and Klebsiella pneumoniae: prevalence of TEM-52 in Korea.

Authors:  H Pai; S Lyu; J H Lee; J Kim; Y Kwon; J W Kim; K W Choe
Journal:  J Clin Microbiol       Date:  1999-06       Impact factor: 5.948

Review 6.  beta-Lactamases in laboratory and clinical resistance.

Authors:  D M Livermore
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

7.  Detection of extended-spectrum beta-lactamases in clinical isolates of Klebsiella pneumoniae and Escherichia coli.

Authors:  G A Jacoby; P Han
Journal:  J Clin Microbiol       Date:  1996-04       Impact factor: 5.948

8.  Extended-spectrum beta-lactamases in enterobacteriaceae in Buenos Aires, Argentina, public hospitals.

Authors:  M Quinteros; M Radice; N Gardella; M M Rodriguez; N Costa; D Korbenfeld; E Couto; G Gutkind
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

9.  Bactericidal killing activities of cefepime, ceftazidime, cefotaxime, and ceftriaxone against Staphylococcus aureus and beta-lactamase-producing strains of Enterobacter aerogenes and Klebsiella pneumoniae in an in vitro infection model.

Authors:  S M Palmer; S L Kang; D M Cappelletty; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191

10.  Bacterial cell wall recycling provides cytosolic muropeptides as effectors for beta-lactamase induction.

Authors:  C Jacobs; L J Huang; E Bartowsky; S Normark; J T Park
Journal:  EMBO J       Date:  1994-10-03       Impact factor: 11.598
View more
  7 in total

1.  Prevalence of derepressed ampC mutants and extended-spectrum beta-lactamase producers among clinical isolates of Citrobacter freundii, Enterobacter spp., and Serratia marcescens in Korea: dissemination of CTX-M-3, TEM-52, and SHV-12.

Authors:  Jungmin Kim; Yu-Mi Lim
Journal:  J Clin Microbiol       Date:  2005-05       Impact factor: 5.948

2.  SHV-type extended-spectrum beta-lactamase production is associated with Reduced cefepime susceptibility in Enterobacter cloacae.

Authors:  Dóra Szabó; Robert A Bonomo; Fernanda Silveira; A William Pasculle; Carla Baxter; Peter K Linden; Andrea M Hujer; Kristine M Hujer; Kathleen Deeley; David L Paterson
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

3.  Bacteremia due to extended-spectrum-beta-lactamase-producing Enterobacter cloacae: role of carbapenem therapy.

Authors:  Ching-Chi Lee; Nan-Yao Lee; Jing-Jou Yan; Hsin-Chun Lee; Po-Lin Chen; Chia-Ming Chang; Chi-Jung Wu; Nai-Ying Ko; Li-Rong Wang; Chih-Hsien Chi; Wen-Chien Ko
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

4.  Prevalence of newer beta-lactamases in gram-negative clinical isolates collected in the United States from 2001 to 2002.

Authors:  Ellen S Moland; Nancy D Hanson; Jennifer A Black; Ashfaque Hossain; Wonkeun Song; Kenneth S Thomson
Journal:  J Clin Microbiol       Date:  2006-09       Impact factor: 5.948

5.  Prevalence, microbiology, and clinical characteristics of extended-spectrum beta-lactamase-producing Enterobacter spp., Serratia marcescens, Citrobacter freundii, and Morganella morganii in Korea.

Authors:  S-H Choi; J E Lee; S J Park; M-N Kim; E J Choo; Y G Kwak; J-Y Jeong; J H Woo; N J Kim; Y S Kim
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-08       Impact factor: 3.267

6.  Emergence of antibiotic resistance during therapy for infections caused by Enterobacteriaceae producing AmpC beta-lactamase: implications for antibiotic use.

Authors:  Sang-Ho Choi; Jung Eun Lee; Su Jin Park; Seong-Ho Choi; Sang-Oh Lee; Jin-Yong Jeong; Mi-Na Kim; Jun Hee Woo; Yang Soo Kim
Journal:  Antimicrob Agents Chemother       Date:  2007-12-17       Impact factor: 5.191

7.  Prevalence and impact of extended-spectrum β-lactamase production on clinical outcomes in cancer patients with Enterobacter species bacteremia.

Authors:  Sun Jong Kim; Ki-Ho Park; Jin-Won Chung; Heungsup Sung; Seong-Ho Choi; Sang-Ho Choi
Journal:  Korean J Intern Med       Date:  2014-08-28       Impact factor: 2.884
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.